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Neural tube defects (NTDs), including spina biﬁda and anencephaly, are common birth defects of the central
nervous system. The complex multigenic causation of human NTDs, together with the large number of pos-
sible candidate genes, has hampered efforts to delineate their molecular basis. Function of folate one-
carbon metabolism (FOCM) has been implicated as a key determinant of susceptibility to NTDs. The glycine
cleavage system (GCS) is a multi-enzyme component of mitochondrial folate metabolism, and GCS-encoding
genes therefore represent candidates for involvement in NTDs. To investigate this possibility, we sequenced
the coding regions of the GCS genes: AMT, GCSH and GLDC in NTD patients and controls. Two unique non-
synonymous changes were identiﬁed in the AMT gene that were absent from controls. We also identiﬁed a
splice acceptor site mutation and ﬁve different non-synonymous variants in GLDC, which were found to sig-
niﬁcantly impair enzymatic activity and represent putative causative mutations. In order to functionally test the
requirement for GCS activity in neural tube closure, we generated mice that lack GCS activity, through muta-
tion of AMT. Homozygous Amt
2/2 mice developed NTDs at high frequency. Although these NTDs were not pre-
ventable by supplemental folic acid, there was a partial rescue by methionine. Overall, our ﬁndings suggest
that loss-of-function mutations in GCS genes predispose to NTDs in mice and humans. These data highlight
the importance of adequate function of mitochondrial folate metabolism in neural tube closure.
INTRODUCTION
Neural tube defects (NTDs), such as spina biﬁda and anen-
cephaly, are severe birth defects that result from failure of
closure of the neural folds during embryonic development
(1). Although NTDs are among the commonest birth defects
in humans, the causes are still not well understood. This is
most likely due to their complex, multifactorial causation
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and environmental factors (2–4). The potential complexity
of NTD genetics is illustrated by the fact that more than 200
different genes give rise to NTDs when mutated in mice
(5,6). Moreover, inheritance patterns in humans suggest a mul-
tigenic model in which an affected individual may carry two
or more risk alleles, which by themselves may be insufﬁcient
to cause NTDs (2).
Folate one-carbon metabolism (FOCM) is strongly impli-
cated as a determinant of susceptibility to NTDs since sub-
optimal maternal folate status and/or elevated homocysteine
are established risk factors, whereas periconceptional maternal
folic acid supplementation can reduce the occurrence and re-
currence of NTDs (7,8). Nevertheless, the precise mechanism
by which folate status inﬂuences NTD risk remains elusive
(7,9). FOCM comprises a network of enzymatic reactions
required for synthesis of purines and thymidylate for DNA
synthesis, and methionine, which is required for methylation
of biomolecules (Fig. 1A) (9). In addition to the cytosol,
FOCM also operates in mitochondria, supplying extra one-
carbon units to the cytosolic FOCM as formate (Fig. 1A) (10).
Genes that are functionally related to folate metabolism
have been subjected to intensive genetic analysis in relation
to NTD causation, principally through association studies
(reviewed in 3,4,11). In the most extensively studied gene,
MTHFR, the c.677C.T SNP is associated with NTDs in
some, but not all, populations. However, other FOCM-related
genes have largely shown non-signiﬁcant or only mild associa-
tions. Given the apparently complex inheritance of the major-
ity of human NTDs, many association studies have been
hampered by limitations on sample size. Moreover, although
positive associations have been noted for other genes includ-
ing DHFR, MTHFD1, MTRR and TYMS (12,13), these have
not been replicated in all populations, and additional studies
are required. The hypothesis that genetically determined ab-
normalities of folate metabolism may contribute to NTD sus-
ceptibility is supported by the observation of defects of
thymidylate biosynthesis in a proportion of primary cell
lines derived from NTDs (14). However, these defects do
not correspond with known polymorphisms in FOCM-related
genes. Overall, it appears likely that genetic inﬂuences on
folate metabolism remain to be identiﬁed in many NTDs.
A potential link between mitochondrial FOCM and NTDs
was suggested by the ﬁnding of an association of increased
NTD risk with an intronic polymorphism in MTHFD1L (15).
Another component of mitochondrial FOCM, the glycine
cleavage system (GCS), acts to break down glycine to
donate one-carbon units to tetrahydrofolate (THF), generating
5,10-methylenetetrahydrofolate (methylene-THF; Fig. 1B)
(16,17). The GCS consists of four enzyme components, each
of which is required for the glycine cleavage reaction
(18,19). The components—glycine dehydrogenase (decarb-
oxylating) (GLDC; P-protein), aminomethlyltransferase
(AMT; T-protein), glycine cleavage system protein H
(GCSH; H-protein) and dihydrolipoamide dehydrogenase
(DLD; L-protein)—are encoded by distinct genes: GLDC,
AMT, GCSH and DLD, respectively. The functions of
GLDC, AMT and GCSH are speciﬁc to the GCS, whereas
DLD encodes a housekeeping enzyme. GCS components
have been found to be abundantly expressed in the neuroepi-
thelium during embryogenesis in the rat (20).
We hypothesized that modulation of GCS activity has the
potential to inﬂuence efﬁcacy of cellular FOCM during the
period of neural tube closure and, hence, susceptibility to
NTDs. Therefore, in the current study, we screened genes en-
coding GCS components for possible mutations in NTD
patients and controls. We tested variant proteins for loss of
function by enzymatic assay and mice lacking GCS function
were generated, to test the effect on embryonic development.
RESULTS
The hypothesis that genes of the GCS represent candidates for
involvement in NTDs prompted us to screen for potential
mutations in patient samples. Coding exons of AMT (9
exons), GCSH (5 exons) and GLDC (25 exons) were
sequenced in a total of 258 NTD patients comprising cohorts
from Japan, the UK and Sweden. Each of the major categories
of NTDs was represented among study samples, including an-
encephaly (n ¼ 38), spina biﬁda (n ¼ 198) and craniora-
chischisis (n ¼ 22).
Figure 1. Schematic diagrams summarizing the key reactions of folate-
mediated one-carbon metabolism and the GCS. (A) Folates donate and
accept one-carbon units in the synthesis of purines, thymidylate and methio-
nine. Mitochondrial FOCM supplies one-carbon units to the cytoplasm via
formate. The GCS is a key component of mitochondrial FOCM that breaks
down glycine and generates 5,10-methylene-THF from THF. Genes encoding
enzymes for each reaction are indicated in italics. DHF, dihydrofolate; THF,
tetrahydrofolate. (B) Summary of the GCS. The glycine cleavage reaction is
catalysed by the sequential action of four individual enzymes: GLDC,
GCSH, AMT and DLD. The ﬁrst three of these (shaded grey) are speciﬁc to
the GCS. Glycine is broken down into CO2 and NH3, and donates a one-
carbon unit (indicated in bold) to THF, generating 5,10-methylene-THF.
The other carbon in glycine (indicated in italics) enters CO2.
Human Molecular Genetics, 2012, Vol. 21, No. 7 1497In AMT, we identiﬁed two novel sequence variants pre-
dicted to result in non-synonymous missense changes,
c.589G.C (D197H) and c.850G.C (V284L), in anencephaly
and spina biﬁda patients, respectively, from the UK cohort
(Table 1). Neither variant was present in 526 UK or 36 Japa-
nese control subjects or in the SNP databases dbSNP and 1000
Genomes. An additional missense variant, E211K, was also
identiﬁed in three spina biﬁda patients, two from the UK
and one from Sweden. Causative mutations in AMT have
been found previously in an autosomal recessive inborn
error of metabolism, non-ketotic hyperglycaemia (NKH)
(17). The E211K variant had previously been identiﬁed in
an NKH family but was established as likely to be a non-
functional polymorphism by segregation (21). Therefore, this
variant is considered unlikely to be causally related to NTDs.
Exon sequencing of GCSH revealed eight single-base sub-
stitutions, one of which (c.53C.T, p.A18V) was a novel
change found in both an NTD and a single control
(Table 1). The others all corresponded to known SNPs,
which did not suggest a role for GCSH in NTDs.
Next we turned our attention to GLDC, in which we identi-
ﬁed 27 single-base substitutions (Table 1), including 11 silent
nucleotide changes, 15 non-synonymous changes and a spli-
cing acceptor variant of intron 19 (c.2316-1G.A). The
Table 1. Nucleotide changes in NTD patients and controls identiﬁed by exon sequencing of AMT, GLDC and GCSH
Location Nucleotide
change
Effect Number of mutation carriers in
UK cohorts
Number of mutation carriers
in the Japanese cohort
Number of mutation carriers


































Exon 2 c.103A.C p.R35R 0 1 0 0 0 —
c.214A.G p.T72A 0 0 0 1 0 —
Exon 6 c.623C.A p.A208D 0 2 0 0 0 —
c.631G.A p.E211K
d 2 (SBA) 0 0 0 1 —
c.589G.C p.D197H 0 0 1 (An) 0 0 —
Exon 7 c.825T.A p.N275K 0 1 0 0 0 —
c.850G.C p.V284L 1 (SBA) 0 0 0 0 —
GLDC
Exon 1 c.52G.T p.G18C 2 (SBO/SBA) 2 0 0 2 (SBA) 2 84%
Exon 5 c.668C.G p.P223R 0 0 0 1 0 — 92%
Exon 12 c.1508A.C p.E503A 1 (SBA) 0 0 0 0 0 —
c.1512G.C p.E504D 1 (SBA) 0 0 0 0 0 99%
c.1519G.C p.G507R 1 (An) 0 0 0 0 0 17%
c.1525C.G p.P509A
e 1 (An) 0 0 0 0 0 41%
c.1550G.C p.S517T 0 0 0 0 1 (SBA) 0 —
c.1570G.C p.V524L 1 (SBA) 0 0 0 0 0 34%
Exon 14 c.1705G.A p.A569T
f 3 (SBA/SBO/
SBO)
1 0 0 1 (SBA) 0 40%
Exon 17 c.1953T.C p.H651H 0 1 0 0 0 — —
Exon 19 c.2203G.T p.V735L 0 2 0 0 0 — 81%
Intron 19 c.2316-1G.A splice 1 (SBA) 0 0 0 0 —
Exon 20 c.2380G.A p.A794T 2 (SBASBA) 0 0 0 2 (SBA) 2 88%
c.2406G.A p.A802A 1 (An) 0 0 0 0 0 —
Exon 21 c.2474G.A p.G825D 0 0 1 (An) 0 0 — 24%
c.2487C.T p.A829A 0 1 0 0 0 — —
c.2565A.C p.A855A 1 (An) 0 0 0 0 — —
Exon 23 c.2746C.T p.L916L 1 (Crn) 0 0 0 0 — —
Exon 25 c.2964G.A p.R988R 0 0 0 0 1 (SBA) 0 —
c.2965A.G p.I989V 0 1 0 0 0 0 130%
GCSH
Exon 1 c.53C.T p.A18V 1 (An) 1 0 0 — —
All nucleotide changes were found in heterozygous form. One individual carried c.52G.T and c.1705G.Ai nGLDC, whereas no other individuals carried more
than one of the nucleotide changes listed here. Eight silent polymorphisms and four missense variants present in dbSNP (http://www.ncbi.nlm.nih.gov/projects/
SNP/) are not listed in this table and include: AMT: c.954G.A (p.R318R, rs11715915); GLDC: c.249G.A (p.G83G, rs12341698), c.438G.A (p.T146T,
rs13289273), c.501G.A (p.E167E, rs13289273), c.660C.T (p.L220L, rs2228095), c.666T.C (p.D222D, rs12004164), c.671G.A (p.R224H, rs28617412) and
c.1384C.G (p.L462V, rs73400312); and for GCSH: c.62T.C (p.S21L, rs8052579), c.90C.G (p.P30P, rs8177847), c.159C.T (p.F53F, rs177876), c.218A.G
(N73S, rs8177876), c.252T.C (Y84Y, rs8177907) and c.261C.G (L87L, rs8177908). Grey shading indicates loss-of-function mutations, based on enzymatic
activity in the in vitro expression study or splicing defect.
aResidual enzymatic activity of GLDC mutant protein is expressed as %activity of the wild-type enzyme (Fig. 2).
bSBA, spina biﬁda aperta; SBO, spina biﬁda occulta; An, anencephaly; Crn, craniorachischisis.
cTotal number of UK, Japanese or Swedish NTD patients.
dThis variant was previously established as likely to be a non-functional polymorphism by segregation in an NKH family (21).
eA biochemical test of folate metabolism, the dU suppression test, was previously performed on primary ﬁbroblasts derived from this patient and showed a defect
of thymidylate biosynthesis to be present (14).
fp.A569T has previously been reported as a pathogenic mutation in a patient with typical NKH (21).
1498 Human Molecular Genetics, 2012, Vol. 21, No. 7latter is deduced to abolish normal splicing of the GLDC
mRNA, with predicted skipping of exon 19 resulting in loss
of the reading frame. Among the 15 missense variants identi-
ﬁed in GLDC, 5 were unique to the NTD group, being absent
from all 562 control individuals as well as from the SNP data-
bases. A further three novel variants were found only in con-
trols, whereas the remainder were found in both NTDs and
controls, and included previously reported SNPs.
We investigated the possible functional effects of GLDC
missense variants by expressing wild-type and mutant cDNA
constructs in COS7 cells, followed by enzymatic assay of
GLDC activity involving a decarboxylation reaction using
[1-
14C]glycine (22). Twelve GLDC variants were tested, in-
cluding those that were unique to NTD patients and, therefore,
hypothesized to be potentially pathogenic (Fig. 2). The L462V
variant, which corresponds to a known SNP (rs73400312), was
included as an example of a known normally occurring form.
Five of the missense changes, G507R, P509A, V524L, A569T
and G825D, resulted in a signiﬁcant reduction in GLDC activ-
ity compared with the wild-type protein (P , 0.001). Notably,
all ﬁve of these deleterious variants were present solely in
NTD cases, whereas none of the variants that were unique
to controls (P223R, V735L and I989V) showed loss of
enzymatic function. In the case of G18C and A794T, which
occurred in both NTDs and controls, there was no signiﬁcant
loss of enzymatic activity, suggesting that these are unlikely
to be causative mutations.
Having identiﬁed putative mutations in AMT and GLDC in
NTD patients, we hypothesized that loss of GCS function
could predispose to development of NTDs. In order to directly
test the functional requirement for GCS activity in neural tube
closure, we generated mice that lacked GCS activity, using a
gene trap (OmniBank, OST181110) of the Amt gene. The
vector was located in intron 2, resulting in a truncated tran-
script that lacked exons 3–9 (Fig. 3). The efﬁcacy of the gene-
trap vector in trapping expression of Amt (Amt
2) was con-
ﬁrmed by RT-PCR analysis (Fig. 3). Heterozygous Amt
+/2
mice were viable and fertile and exhibited no obvious malfor-
mations. Homozygous Amt
2/2 mice were not observed among
post-natal litters from heterozygote intercrosses, and so fetuses
were examined at embryonic day (E) 17.5. Strikingly, 87% of
Amt
2/2 fetuses (34 out of 39) exhibited NTDs, whereas no
malformations were observed in Amt
+/+ (n ¼ 33) or Amt
+/2
Figure 2. Characterization of GLDC missense mutations identiﬁed through
DNA sequence analysis. (A) The schematic represents the 1020 amino acid
residue GLDC polypeptide with the positions of the identiﬁed missense var-
iants indicated. Mutations conferring signiﬁcantly reduced activity (B) are
indicated in bold. The leader peptide for mitochondrial import (shaded
black) and the lysine 754-binding site for the co-factor pyridoxal phosphate
(PLP) are indicated (49). (B) Enzymatic activity of GLDC missense variants.
Expression vectors with wild-type and mutant GLDC cDNAs were transfected
into COS7 cells for the evaluation of GLDC activity, which is expressed as
relative activity (%) of cells expressing wild-type cDNA (shaded grey). The
L462V GLDC enzyme (shaded grey) was tested as an example of a normally
occurring variant (rs73400312). Variant proteins whose activities were signiﬁ-
cantly diminished compared with wild-type are indicated by black shading.
The I989V variant, identiﬁed in a control parent, showed signiﬁcantly elevated
activity. Values are given as mean+SD of triplicate experiments (∗P , 0.05;
∗∗P , 0.01, compared with wild-type).
Figure 3. Generation of Amt knockout mouse by gene trapping. (A) The loca-
tion of the gene-trap vector in Amt intron 2 in the ES cell line OST181110 was
determined by inverse PCR. Mice carrying this mutation were generated using
standard methods of blastocyst microinjection with OST181110 ES cells to
generate chimeras, and germ-line transmission. LTR, long terminal repeats;
SA, splicing acceptor site; Neo, neomycin phosphotransferase gene; pA, poly-
adenylation sequence. (B) For genotyping, mouse genomic DNA was sub-
jected to allele-speciﬁc ampliﬁcation with F, R1 and R2 primers
(Supplementary Material, Table S1). A genomic fragment of 320 bp was amp-
liﬁed from the wild-type allele, whereas a 233 bp fragment was ampliﬁed from
the Amt-mutant allele. (C) RT-PCR analysis of Amt mRNA expressed in the
brain and liver of Amt-mutant mice. Primers in exon 1–2 generated a
121 bp band irrespective of mouse genotypes. RT-PCR in which either one
(f2-r2) or both (f3-r3) primers were located in exons 3′ to the insertion site pro-
duced 220 and 355 bp cDNA fragments, respectively, in Amt
+/+ and Amt
+/2
mice, but not in Amt
2/2. The Amt mRNA in mice carrying the trap vector was,
therefore, aberrantly spliced at the end of exon 2, resulting in truncation of Amt
mRNA in Amt
2/2 mice.
Human Molecular Genetics, 2012, Vol. 21, No. 7 1499(n ¼ 66) fetuses. Defects mainly comprised exencephaly
(82%), in which the cranial neural folds persistently failed to
close (Fig. 4). There was also a low frequency of the more
severe condition, craniorachischisis (5%), in which the
neural tube remains open from the mid- and hindbrain, and
throughout the spinal region (Fig. 4). Fetal liver samples
were subjected to enzyme assay to determine overall activity
of the GCS. In Amt
2/2 mice, overall GCS activity was effect-
ively ablated being below the detection level of the assay
(0.01 nmoles of
14CO2 formed/gram protein/h), consistent
with the Amt
2 allele being a functional null (22) (Fig. 4).
These ﬁndings conﬁrm that AMT function is essential for
GCS activity, and that the latter is necessary for successful
neural tube closure.
Given that GCS is a component of FOCM (Fig. 1), we eval-
uated the possible prevention of NTDs by folate-related meta-
bolites. Maternal supplementation was performed with folic
acid, thymidine monophosphate (TMP), methionine or me-
thionine plus TMP (23). Neither folic acid nor TMP signiﬁ-
cantly affected the frequency of NTDs among the
homozygous Amt
2/2 offspring. However, we observed a sig-
niﬁcant protective effect of maternal supplementation with
methionine or methionine plus TMP, compared with the non-
treated group (P , 0.05; Fig. 5).
DISCUSSION
NTDs remain among the commonest human birth defects and
understanding their genetic basis presents a considerable
challenge owing to their multigenic inheritance and the poten-
tial inﬂuence of environmental factors, either predisposing or
ameliorating. Several lines of evidence indicate a requirement
for FOCM in neural tube closure and, therefore,
GCS-encoding genes provide excellent candidates for possible
involvement in NTD susceptibility. We identiﬁed putative
mutations in AMT and GLDC which include a splice acceptor
mutation and a number of non-synonymous variants that were
absent from a large group of population-matched controls, as
well as from public SNP databases. In the case of GLDC, en-
zymatic assay conﬁrmed that several mutations resulted in sig-
niﬁcant loss of enzyme activity. Finally, in vivo functional
evidence of a requirement for GCS function in neural tube
closure was provided by the occurrence of NTDs in Amt
2/2
mice lacking GCS activity. Together these ﬁndings indicate
that mutations in GLDC and AMT predispose to NTDs in
both mice and humans.
Where parental samples were available (6 of the 11 NTD
cases that involved putative mutations in GLDC), we demon-
strated parent-to-child transmission (Supplementary Material,
Table S2). Six were instances of maternal transmission and
one involved paternal transmission. We hypothesize that
absence of an overt NTD phenotype in parents who carry a de-
ﬁcient GLDC allele may result from incomplete penetrance, or
lack of additional genetic or environmental factors which are
predicted to be necessary for NTDs owing to their multifactor-
ial aetiology. We also note that partial penetrance is a feature
of numerous mouse models of NTDs (5,8).
Inherited GCS deﬁciency, owing to mutation of AMT and/or
GLDC, has been shown to cause NKH in humans (17). NKH is
a rare, autosomal recessive, inborn error of metabolism, char-
acterized by accumulation of glycine and encephalopathy-like
neurological signs, including coma and convulsive seizures in
neonates. GCS activity is greatly diminished in NKH patients
and they would, therefore, be predicted to be at increased risk
of NTDs. It is possible that NTDs may occur in combination
with NKH but as anencephaly is a lethal condition, co-existing
Figure 4. Mice lacking GCS activity exhibit NTDs. (A) Phenotypes of Amt
mutant mice. NTDs were evident in the majority (88%) of Amt
2/2 fetuses
(examples shown are at E17.5). Various types of NTDs were observed in
Amt
2/2 fetuses, which principally affected the cranial region; a, no NTDs;
b, small exencephaly (dotted circle); c–e, large exencephaly; f, craniora-
chischisis. (B) Enzymatic activity of the GCS in Amt knockout mice.
Amt
+/2 and Amt
2/2 fetuses had signiﬁcantly lower GCS activity in the
liver than Amt
+/+ fetuses, with activity in Amt
2/2 samples below the level
of detection (∗∗P , 0.01 compared with Amt
+/+).
Figure 5. Maternal supplementation of Amt mutant embryos with folic acid,
TMP or methionine. Maternal treatment with folic acid (n ¼ 10 homozygous
mutant fetuses) or TMP (n ¼ 12) had no signiﬁcant effect on NTD frequency,
whereas the frequency of unaffected embryos was signiﬁcantly increased
following treatment with methionine (n ¼ 12) or methionine plus TMP
group (n ¼ 12). The asterisk indicates signiﬁcant difference compared with
non-treated group (P , 0.05).
1500 Human Molecular Genetics, 2012, Vol. 21, No. 7NKH would go undetected. Lack of NTDs in NKH patients
may also reﬂect the multigenic nature of NTDs, which
require the presence of additional risk alleles in non-GCS
genes. NKH is a relatively rare condition, with a prevalence
of 1/63 000 births in British Columbia (24) and 1/250 000 in
the USA (25). It is therefore possible that an increased risk
of NTDs among carriers of GCS mutations in NKH families
may not have been noted and this possibility is worthy of
investigation. Based on estimated carrier frequency and the
incidence of mutations among NTD patients, we predict that
NTDs might be expected among 1/150 of the siblings of
NKH patients (see Supplementary Material, Table S3 for esti-
mate calculation). One case report of an NKH patient with a
GLDC mutation describes the additional presence of spinal
cord hydromyelia (19). This condition is often associated
with low spinal defects (involving secondary neurulation),
but it is also possible that the expanded spinal canal was
also present at a higher level and might indicate a limited
defect in primary neurulation.
The mutations described in the current study were all
present in heterozygous form and, therefore, are hypothesized
to be insufﬁcient to cause NKH while predisposing to NTDs.
For example, in the current study we found four NTD patients
and one control individual to be heterozygous for the A569T
mutation, which is shown to result in reduced enzyme activity.
This mutation was previously identiﬁed in a Caucasian patient
with typical NKH, in combination with a second mutation,
P765S (26), conﬁrming that it is deleterious in vivo. Hence,
we predict that, depending on the co-existing genetic milieu,
the A569T variant may cause NKH, predispose to NTDs or
be compatible with normal development.
The high incidence of NTDs in AMT mutant mice is particu-
larly notable as NTDs have not previously been found to be a
common feature of mouse models deﬁcient for folate-
metabolizing enzymes. This includes null mutants that have
been reported for eight other genes that encode enzymes in
FOCM (Fig. 1A) (27). Four have normal morphology at
birth (Cbs, Mthfd1, Mthfr and Shmt1)( 28–31), Mthfd2 null
embryos die by E15.5 but neural tube closure is complete
(32) and null mutants for Mtr, Mtrr and Mthfs die before
E9.5, prior to neural tube closure (33–35). Although analysis
of mouse mutants has not supported a role for single-gene
mutations in FOCM as major causes of NTDs, a requirement
for cellular uptake of folate for neural tube closure has been
demonstrated in Folr1 null embryos, in which NTDs occur
when rescued from early lethality by folic acid supplementa-
tion (36). There is also considerable evidence for possible in-
volvement of gene–environment and/or gene–gene
interactions in NTDs. For example, in Pax3 mutant (splotch)
embryos, which exhibit a defect of thymidylate biosynthesis,
dietary folate-deﬁciency increases the frequency of cranial
NTDs (23,37). Similarly, a diet deﬁcient in folate and
choline causes NTDs in Shmt1 mutant embryos, whereas
Shmt1 and Pax3 mutations exhibit genetic interaction (38).
Regarding the mechanisms by which GCS mutations affect
neural tube closure, a key question is whether NTDs are
caused by impairment of FOCM or by another cause such as
glycine accumulation. Modelling of hepatic FOCM, based
on biochemical properties of folate-metabolizing enzymes
(39), predicts that loss of the mitochondrial GCS reaction
would reduce the efﬂux rate of formate to the cytosol by
 50%. This results in reduced synthesis of purines and thymi-
dylate, which are essential for the rapid cell division in the
closing neural folds. Interestingly, a UK patient with anen-
cephaly who was found to carry the GLDC loss-of-function
mutation P509A in the current study (Table 1) was previously
found to have impaired thymidylate biosynthesis, assayed in
cultured ﬁbroblasts (14). These ﬁndings support the hypothet-
ical link between diminished GLDC function, reduced thymi-
dylate biosynthesis and development of NTDs. Reduced
thymidylate biosynthesis and diminished cellular proliferation
are proposed to underlie folate-related cranial NTDs in splotch
(Pax3) mouse mutants (37,38).
As well as impairment of nucleotide biosynthesis, the pre-
dicted effect of diminished GCS activity in reducing produc-
tion of methionine (39) may also be of relevance as
methionine is the precursor for the methyl donor
S-adenosylmethionine. Indeed, metabolic tracing experiments
suggest that  80% of 1C units in the methylation cycle are
generated within mitochondrial FOCM (40). Impairment of
the methylation cycle and/or DNA methylation is known to
cause NTDs in mice (41) and is proposed as a possible
cause of human NTDs (7,42). It was therefore notable that
we found a preventive effect of methionine supplementation
in Amt
2/2 mice. Together, these ﬁndings suggest that
FOCM, required for both thymidylate biosynthesis and methy-
lation reactions that are essential for neural tube closure, may
be functionally deﬁcient in individuals who have mutations in
GLDC or AMT.
MATERIALS AND METHODS
Patient cohorts and sequencing
Mutation analysis by DNA sequencing was performed on all
exons of AMT, GCSH and GLDC as described (26). Cases
comprised Japanese patients with anencephaly (n ¼ 14) and
two separate cohorts of UK patients with a diagnosis of anen-
cephaly (combined n ¼ 24), spina biﬁda (n ¼ 122) or cranior-
achischisis (n ¼ 22). In addition, the exons of AMT, GCSH
and GLDC were sequenced in 76 Swedish patients with
spina biﬁda. Unaffected controls, completely sequenced for
these genes, comprised 36 Japanese and 189 unrelated UK
subjects. Exons found to contain missense mutations were
also sequenced in a further cohort of 192 well-characterized
UK controls (43) and in 145 Swedish controls. This study
was approved by the Ethical Committees of Tohoku Univer-
sity School of Medicine, UCL Institute of Child Health, New-
castle University and the Karolinska Institute.
Enzymatic assay of GCS activity and GLDC activity
GCS activity was measured in mouse liver samples by a
decarboxylation reaction using [1-
14C]glycine as described
(22). For analysis of GLDC activity, wild-type and mutant
GLDC cDNAs were cloned into pCAG expression vector,
kindly provided by Professor Jun-ichi Miyazaki (Osaka Uni-
versity, Japan) (44). Constructs were transfected into COS7
cells, which were harvested as described previously and cell
pellets stored at 2808C prior to analysis (45). GLDC
Human Molecular Genetics, 2012, Vol. 21, No. 7 1501enzymatic activity was determined, in triplicate, by exchange
reaction between carbon dioxide and glycine using NaH
14CO3
in the presence of excess recombinant bovine GCSH protein as
described (22). An expression system of lipoylated bovine
GCSH protein in Escherichia coli was kindly provided by
Dr Kazuko Fujiwara (Tokushima University, Japan) (46). Stat-
istical analysis was performed using SPSS software version
11.0 (SPSS, Inc., Chicago, IL, USA).
Knockout of Amt by insertion of a gene-trap vector
Mice carrying a gene-trap allele of Amt (here denoted Amt
2)
were generated at Lexicon Genetics, Inc. (Houston, TX,
USA) using the OST181110 ES cell line. The genomic inser-
tion site of the gene-trap vector was determined by inverse
PCR and localized to intron 2 (Supplementary Material,
Fig. S1). Total RNA was prepared from the mouse liver and
brain at E18 for RT-PCR analysis (Supplementary Material,
Fig. S1 and Table S1). Amt
+/2 mice were backcrossed with
wild-type C57BL/6 mice for nine generations to generate a
congenic line of mice on the C57BL/6 background, for use
in biochemical and histological analyses. This study was
approved by the Animal Experiment Committee of Tohoku
University.
Maternal supplementation with folic acid and related
metabolites
Dams were treated with folic acid (25 mg/kg), thymidine-
1-phosphate (TMP; 30 mg/kg) or L-methionine (70 mg/kg)
by intra-peritoneal injection, 2 h prior to mating and daily
from E7.5–10.5. Doses were based on previous studies
(23,47,48).
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Supplementary Material is available at HMG online.
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